Inspire(US:INSP) Businesswire·2026-01-05 18:19Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, with a deadline for investors to seek lead plaintiff status set for January 5, 2026 [1][3]. Group 1: Allegations and Legal Action - The complaint claims that Inspire Medical and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the company's readiness for its launch [3]. - The law firm Faruqi & Faruqi is investigating potential claims against Inspire Medical and encourages anyone with relevant information to come forward [7]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced significant delays in the launch of the Inspire V device, citing incomplete training and onboarding at treatment centers as major factors [4]. - The company also faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing implanting centers from billing for procedures [4]. - Inspire reported weak demand and excess inventory for the Inspire V, leading to a drastic cut in its 2025 earnings guidance by over 80% [5]. - Following these announcements, Inspire's stock price plummeted by more than 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [5].